Design Therapeutics, Inc. (DSGN)
10.68
-0.38
(-3.44%)
USD |
NASDAQ |
Oct 30, 16:00
10.66
-0.02
(-0.19%)
After-Hours: 20:00
Design Therapeutics Enterprise Value : 463.62M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 463.62M |
| October 29, 2026 | 487.40M |
| October 28, 2026 | 488.65M |
| October 27, 2026 | 460.49M |
| October 26, 2026 | 442.34M |
| October 23, 2026 | 436.09M |
| October 22, 2026 | 451.73M |
| October 21, 2026 | 466.75M |
| October 20, 2026 | 489.91M |
| October 19, 2026 | 461.12M |
| October 16, 2026 | 440.47M |
| October 15, 2026 | 451.11M |
| October 14, 2026 | 404.17M |
| October 13, 2026 | 407.30M |
| October 12, 2026 | 478.01M |
| October 09, 2026 | 524.32M |
| October 08, 2026 | 514.31M |
| October 07, 2026 | 526.83M |
| October 06, 2026 | 544.35M |
| October 05, 2026 | 572.51M |
| October 02, 2026 | 567.50M |
| October 01, 2026 | 561.25M |
| September 30, 2026 | 581.90M |
| September 29, 2026 | 585.03M |
| September 28, 2026 | 568.76M |
| Date | Value |
|---|---|
| September 25, 2026 | 553.74M |
| September 24, 2026 | 561.25M |
| September 23, 2026 | 568.76M |
| September 22, 2026 | 618.82M |
| September 21, 2026 | 580.65M |
| September 18, 2026 | 561.25M |
| September 17, 2026 | 596.92M |
| September 16, 2026 | 577.83M |
| September 15, 2026 | 560.31M |
| September 14, 2026 | 641.35M |
| September 11, 2026 | 710.81M |
| September 10, 2026 | 721.45M |
| September 09, 2026 | 735.22M |
| September 08, 2026 | 748.36M |
| September 04, 2026 | 742.73M |
| September 03, 2026 | 735.84M |
| September 02, 2026 | 767.14M |
| September 01, 2026 | 742.73M |
| August 31, 2026 | 739.60M |
| August 28, 2026 | 740.85M |
| August 27, 2026 | 749.61M |
| August 26, 2026 | 770.89M |
| August 25, 2026 | 776.52M |
| August 24, 2026 | 748.36M |
| August 21, 2026 | 733.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Palvella Therapeutics, Inc. | 1.876B |
| Agenus, Inc. | 556.15M |
| Amgen, Inc. | 295.24B |
| Anika Therapeutics, Inc. | 267.21M |
| BioCryst Pharmaceuticals, Inc. | 2.646B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.16M |
| Total Expenses (Quarterly) | 20.16M |
| EPS Diluted (Quarterly) | -0.3226 |
| Earnings Yield | -11.05% |
| Normalized Earnings Yield | -11.05 |